NAMSW
NewAmsterdam Pharma Co N.V.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 7 ▲ NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and…
- Oct 30 ▼ Short interest jumps 45.2% to 61
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 0 trimmed or exited.
- Short sellersBUILDING
Short interest +45.2% to 61 shares. 1.0 days to cover, ≈0.0% of shares.
- TrendDOWNTREND
10% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | $318.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
3 filings · 1 bullish · 0 bearish · 2 neutral- NEUTRAL 8-KJun 3, 2026
NewAmsterdam Pharma filed an 8-K reporting the results of its 2026 annual general meeting, where…
No immediate trading catalyst. The ESPP is a standard employee benefit with minimal near-term dilution. Monitor for future ESPP purchase periods and any subsequent share issuances.
- BULLISH 8-KMay 7, 2026
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M…
The upcoming PREVAIL interim analysis (Q4 2026, result Q1 2027) is a major binary catalyst. Positive outcome could drive significant upside, while failure would severely impact value. Regulatory…
- NEUTRAL 8-KApr 24, 2026
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with…
Monitor the next 10-Q filing for disclosure of the full separation agreement and any impact on compensation expenses. The departure of a financial officer warrants attention, but the orderly…
All NAMSW filing & press-release reports (3)
- 8-K reportJun 3, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 24, 2026